uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
In Vitro and In Vivo Efficacies of Mefloquine-Based Treatment against Alveolar Echinococcosis
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Cell and Molecular Biology, Microbiology.
Show others and affiliations
2011 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 55, no 2, 713-721 p.Article in journal (Refereed) Published
Abstract [en]

Alveolar echinococcosis (AE) is caused by the metacestode stage of the fox tapeworm Echinococcus multilocularis and causes severe disease in the human liver, and occasionally in other organs, that is fatal when treatment is unsuccessful. The present chemotherapy against AE is based on mebendazole and albendazole. Albendazole treatment has been found to be ineffective in some instances, is parasitostatic rather than parasiticidal, and usually involves the lifelong uptake of large doses of drugs. Thus, new treatment options are urgently needed. In this study we investigated the in vitro and in vivo efficacy of mefloquine against E. multilocularis metacestodes. Treatment using mefloquine (20 mu M) against in vitro cultures of metacestodes resulted in rapid and complete detachment of large parts of the germinal layer from the inner surface of the laminated layer within a few hours. The in vitro activity of mefloquine was dependent on the dosage. In vitro culture of metacestodes in the presence of 24 mu M mefloquine for a period of 10 days was parasiticidal, as determined by murine bioassays, while treatment with 12 mu M was not. Oral application of mefloquine (25 mg/kg of body weight administered twice a week for a period of 8 weeks) in E. multilocularis-infected mice was ineffective in achieving any reduction of parasite weight, whereas treatment with albendazole (200 mg/kg/day) was highly effective. However, when the same mefloquine dosage was applied intraperitoneally, the reduction in parasite weight was similar to the reduction seen with oral albendazole application. Combined application of both drugs did not increase the treatment efficacy. In conclusion, mefloquine represents an interesting drug candidate for the treatment of AE, and these results should be followed up in appropriate in vivo studies.

Place, publisher, year, edition, pages
2011. Vol. 55, no 2, 713-721 p.
National Category
Biological Sciences
URN: urn:nbn:se:uu:diva-149063DOI: 10.1128/AAC.01392-10ISI: 000286422500034PubMedID: 21135182OAI: oai:DiVA.org:uu-149063DiVA: diva2:403773
Available from: 2011-03-15 Created: 2011-03-15 Last updated: 2011-03-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
In the same journal
Antimicrobial Agents and Chemotherapy
Biological Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 135 hits
ReferencesLink to record
Permanent link

Direct link